3rd Quarter - Report

COMPLETE PHARMA HOLDINGS LLC (CP) (FORMERLY: MARATHON PHARMACEUTICALS, LLC) for COMPLETE PHARMA HOLDINGS LLC (CP) (FORMERLY: MARATHON PHARMACEUTICALS LLC)

Firm
Client
Income
—
Expenses
$80,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

S. 289 - The American Cures Act, provisions related to investment in research and development H.R. 1537, S. 1878 - The Advancing Hope Act, provisions related to the Pediatric Rare Disease Priority Review Voucher Program H.R. 6 - The 21st Century Cure Act, Provision related to investment in research and development, FDA reforms and the Pediatric Rare Disease Priority Review Voucher Program Draft bill - The Senate Innovating for Healthier Americans Act, Provisions related to investment in research and development, FDA reforms and the Pediatric Rare Disease Priority Review Voucher Program; Provisions supporting Precision Medicine and Education about Marathon's Initiatives. Discussions related to Marathon's Sale of Legacy Products Role of Marathon Pharmaceuticals, LLC as a rare disease company

LobbyistCovered position, as disclosed
GREGORY ARONIN —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 1537 (114th), H.R. 6 (114th), S. 289 (114th), S. 1878 (114th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.